Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)

Hong Kong · Delayed Price · Currency is HKD

31.16

+0.96 (3.18%)

Aug 21, 2026, 4:08 PM HKT

Market Cap	4.24B
Revenue (ttm)	102.38K -95.8%
Net Income	-145.79M
EPS	-1.23
Shares Out	136.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,300
Open	30.50
Previous Close	30.20
Day's Range	29.50 - 31.50
52-Week Range	13.48 - 33.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 17, 2026

About HKG:3378

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company’s product pipeline includes HX009, a bifunctional anti-PD-1/SIRPα fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPα bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 55

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 3378

Full Company Profile

Financial Performance

In 2025, HKG:3378's revenue was 92,000, a decrease of -95.82% compared to the previous year's 2.20 million. Losses were -131.01 million, 13.1% more than in 2024.

Financial numbers in CNY Financial Statements